How Medicare Drug Price Negotiation Is Changing What Seniors Pay in 2026

Bottom line: In 2026, Medicare beneficiaries who take certain high-cost prescription drugs may see lower out-of-pocket costs. For the first time, Medicare has negotiated prices directly with drug manufacturers for a small group of widely used medications. These new prices—called “Maximum Fair Prices”—take effect January 1, 2026.

This does not apply to every drug or every senior. It applies to specific drugs covered under Medicare Part D. And while many people with high drug costs may benefit, premiums and plan details can still vary.

Why 2026 matters

The Inflation Reduction Act created a new Medicare Drug Price Negotiation Program. Under this program, the Centers for Medicare & Medicaid Services (CMS) selects certain high-spending drugs covered by Medicare and negotiates a lower price directly with the manufacturer.

According to CMS and the U.S. Department of Health and Human Services (HHS), the first 10 negotiated drug prices take effect on January 1, 2026. This is the first time Medicare has used this authority.

What is Medicare drug price negotiation?

Before this law, Medicare was generally prohibited from negotiating drug prices directly with manufacturers. Instead, private Part D plans negotiated separately.

Under the new program, CMS selects certain single-source, brand-name drugs with no generic or biosimilar competition and high overall spending in Medicare. Manufacturers of selected drugs are required to negotiate or face financial penalties.

The result is a negotiated price known as the Maximum Fair Price (MFP). Medicare Part D plans must offer these drugs at or below that price beginning in 2026.

Which drugs are in the first round?

In August 2024, HHS announced the first 10 drugs selected for negotiation. They are commonly used to treat conditions that affect millions of older adults, including heart disease, diabetes, autoimmune conditions, and cancer.

The first 10 drugs are:

Eliquis (apixaban) – blood thinner for stroke prevention and atrial fibrillation
Jardiance (empagliflozin) – type 2 diabetes and heart failure
Xarelto (rivaroxaban) – blood thinner
Januvia (sitagliptin) – type 2 diabetes
Farxiga (dapagliflozin) – diabetes, heart failure, kidney disease
Entresto (sacubitril/valsartan) – heart failure
Enbrel (etanercept) – autoimmune conditions like rheumatoid arthritis
Imbruvica (ibrutinib) – certain blood cancers
Stelara (ustekinumab) – autoimmune conditions
Fiasp (insulin aspart) – rapid-acting insulin

These drugs were selected because they account for high spending in Medicare and have been on the market long enough to qualify under the law.

How is the “Maximum Fair Price” set?

CMS does not simply impose a flat discount. Instead, it considers several factors, including:

The drug’s clinical benefit compared to alternatives
Research and development costs
Production and distribution costs
Federal financial support received during development
Data on sales and revenue

CMS and the manufacturer go through a structured negotiation process. The final Maximum Fair Price must meet certain statutory discount requirements based on how long the drug has been on the market.

Independent analysis from KFF explains that the required minimum discount increases as drugs age, meaning older brand-name drugs generally face larger negotiated reductions.

How does this change what you pay at the pharmacy?

The negotiated price applies to Medicare Part D plans. What you pay still depends on your specific plan’s benefit design—your deductible, copayments, and coinsurance.

However, because your cost-sharing is typically based on a percentage of a drug’s price (coinsurance) or tier placement, a lower negotiated price can translate into lower out-of-pocket costs—especially for people taking these medications long term.

If you take one of the 10 selected drugs and are enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage, you may see lower costs in 2026. But the exact amount will vary by plan.

The $2,000 annual out-of-pocket cap

Separate from negotiation, Medicare also introduced a major change to Part D.

Starting in 2025, annual out-of-pocket drug spending for Part D is capped at $2,000. Medicare.gov explains that once you reach this limit in a calendar year, you do not pay additional cost-sharing for covered Part D drugs for the rest of that year.

In 2026, both policies will be in effect:

Negotiated Maximum Fair Prices for certain drugs
A $2,000 cap on annual out-of-pocket spending

People with high drug costs—such as those with cancer, heart failure, diabetes, or autoimmune disease—are most likely to benefit from this combination.

Who benefits most?

The biggest financial impact is expected for:

People taking one or more of the negotiated drugs
Those with multiple chronic conditions
Beneficiaries who previously reached catastrophic coverage levels

For someone who consistently hits the $2,000 cap, overall annual spending may now be more predictable and lower than in prior years.

What does not change

It’s important to understand what this program does not do:

It does not apply to private employer insurance or Marketplace plans.
It does not apply to every Medicare drug—only selected drugs.
It does not eliminate premiums or all cost-sharing.
It does not guarantee lower Part D premiums for everyone.

Part D premiums are still set by private insurance plans. As MedPAC and KFF note, how negotiation affects overall premiums over time remains an area to watch.

What remains uncertain

Several questions are still being studied and debated:

How negotiation will affect Part D premiums in the long term
Whether plans will adjust formularies or tier placement in response
How manufacturers may change pricing strategies in future years
How expanded negotiation rounds (more drugs are scheduled in future years) will affect overall Medicare spending

Additional drugs are scheduled to be selected in future years, expanding the program beyond the first 10.

What seniors and caregivers should do now

If you are on Medicare:

Review your Annual Notice of Change (ANOC) each fall.
Check whether you take one of the negotiated drugs.
Compare Part D plans during Open Enrollment (October 15–December 7).
Confirm how your plan places these drugs on its formulary tiers.
Ask your pharmacist or plan about expected out-of-pocket costs for 2026.

For families helping aging parents, this is a good time to review medication lists and annual drug spending. The new $2,000 cap and negotiated prices may change budgeting needs—but plan details still matter.

What this means for readers

In 2026, Medicare will begin offering lower, negotiated prices for a limited set of high-cost drugs. If you take one of those medications, your out-of-pocket costs may be lower—especially when combined with the $2,000 annual cap.

But this is not a universal price cap, and it does not apply outside Medicare. Premiums, formularies, and plan rules still vary.

The most practical step is simple: review your plan each fall and compare your options carefully. The savings will depend on your specific medications and coverage.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.